These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26048454)

  • 1. LRP receptor family member associated bone disease.
    Lara-Castillo N; Johnson ML
    Rev Endocr Metab Disord; 2015 Jun; 16(2):141-8. PubMed ID: 26048454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
    Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
    J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes.
    Balemans W; Van Hul W
    Endocrinology; 2007 Jun; 148(6):2622-9. PubMed ID: 17395706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRP4 association to bone properties and fracture and interaction with genes in the Wnt- and BMP signaling pathways.
    Kumar J; Swanberg M; McGuigan F; Callreus M; Gerdhem P; Akesson K
    Bone; 2011 Sep; 49(3):343-8. PubMed ID: 21645651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Wnt-beta-catenin signaling in bone metabolism].
    Urano T
    Clin Calcium; 2006 Jan; 16(1):54-60. PubMed ID: 16397351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wnt signaling: a key regulator of bone mass.
    Baron R; Rawadi G; Roman-Roman S
    Curr Top Dev Biol; 2006; 76():103-27. PubMed ID: 17118265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytokines in bone diseases. Wnt signaling and osteoporosis-pseudoglioma syndrome].
    Ozono K
    Clin Calcium; 2010 Oct; 20(10):1520-5. PubMed ID: 20890034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Wnt signaling pathway and bone metabolism.
    Johnson ML; Kamel MA
    Curr Opin Rheumatol; 2007 Jul; 19(4):376-82. PubMed ID: 17551370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Regulation of bone metabolism by pathogenic mutations and polymorphism in the LRP5-Wnt signaling genes].
    Urano T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():95-100. PubMed ID: 18161089
    [No Abstract]   [Full Text] [Related]  

  • 10. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density.
    Van Wesenbeeck L; Cleiren E; Gram J; Beals RK; Bénichou O; Scopelliti D; Key L; Renton T; Bartels C; Gong Y; Warman ML; De Vernejoul MC; Bollerslev J; Van Hul W
    Am J Hum Genet; 2003 Mar; 72(3):763-71. PubMed ID: 12579474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A common LRP4 haplotype is associated with bone mineral density and hip geometry in men-data from the Odense Androgen Study (OAS).
    Boudin E; Steenackers E; de Freitas F; Nielsen TL; Andersen M; Brixen K; Van Hul W; Piters E
    Bone; 2013 Apr; 53(2):414-20. PubMed ID: 23321396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lrp5 and bone formation : A serotonin-dependent pathway.
    Yadav VK; Ducy P
    Ann N Y Acad Sci; 2010 Mar; 1192():103-9. PubMed ID: 20392224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome.
    Ai M; Heeger S; Bartels CF; Schelling DK;
    Am J Hum Genet; 2005 Nov; 77(5):741-53. PubMed ID: 16252235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of Wnt/β-catenin pathway and LRP5 protein in metabolism of bone tissue and osteoporosis etiology].
    Wolski H; Drwęska-Matelska N; Seremak-Mrozikiewicz A; Łowicki Z; Czerny B
    Ginekol Pol; 2015 Apr; 86(4):311-4. PubMed ID: 26117992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel LRP5 gene mutation in a patient with osteoporosis-pseudoglioma syndrome.
    Marques-Pinheiro A; Levasseur R; Cormier C; Bonneau J; Boileau C; Varret M; Abifadel M; Allanore Y
    Joint Bone Spine; 2010 Mar; 77(2):151-3. PubMed ID: 20096619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploiting the WNT Signaling Pathway for Clinical Purposes.
    Johnson ML; Recker RR
    Curr Osteoporos Rep; 2017 Jun; 15(3):153-161. PubMed ID: 28432596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of genetic and epigenetic mechanisms to Wnt pathway activity in prevalent skeletal disorders.
    García-Ibarbia C; Delgado-Calle J; Casafont I; Velasco J; Arozamena J; Pérez-Núñez MI; Alonso MA; Berciano MT; Ortiz F; Pérez-Castrillón JL; Fernández AF; Fraga MF; Zarrabeitia MT; Riancho JA
    Gene; 2013 Dec; 532(2):165-72. PubMed ID: 24096177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRP5, Bone Mass Polymorphisms and Skeletal Disorders.
    Littman J; Yang W; Olansen J; Phornphutkul C; Aaron RK
    Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oropharyngeal skeletal disease accompanying high bone mass and novel LRP5 mutation.
    Rickels MR; Zhang X; Mumm S; Whyte MP
    J Bone Miner Res; 2005 May; 20(5):878-85. PubMed ID: 15824861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A family with osteoporosis pseudoglioma syndrome due to compound heterozygosity of two novel mutations in the LRP5 gene.
    Cheung WM; Jin LY; Smith DK; Cheung PT; Kwan EY; Low L; Kung AW
    Bone; 2006 Sep; 39(3):470-6. PubMed ID: 16679074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.